Nerdwallet Inc vs Sana Biotechnology Inc — how do they compare? Nerdwallet Inc trades at $9.74 (market cap $625.17M), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Sana Biotechnology Inc is the larger of the two by market cap, and Nerdwallet Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nerdwallet Inc for 45 Days and Sana Biotechnology Inc for 23 Days on average.
| NRDS | SANA | |
|---|---|---|
Market Cap | $625.17M | $836.71M |
Volume | 1,321,316 | 4,507,444 |
Sector | Media | Health |
52-Week High | $15.93 | $5.92 |
52-Week Low | $7.58 | $2.68 |
Typical Hold Time | 45 Days | 23 Days |
Enterprise Value | $539.47M | $749.96M |
Signals from Pluang's Aura AI — not financial advice
NerdWallet (NRDS) trades at $9.79, up 7.76% with strong technical momentum and bullish analyst sentiment. The company shows improving fundamentals with revenue growing from $539M in 2022 to $837M in 2025, though Q2 2026 earnings missed expectations. Valuation metrics appear attractive with P/E of 10.87 and P/S of 0.81, while profitability metrics show ROE of 18.16% and net margin of 7.56%.
The stock presents a compelling growth story with accelerating revenue and improving margins, supported by 66.7% analyst buy ratings. Key risks include competitive pressure in organic search and execution challenges in maintaining earnings momentum. The positive cash flow trend and institutional support suggest potential for continued upside if the company can sustain its growth trajectory.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →